2. Academic Validation
  3. A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas

A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas

  • Cancer Cell. 2016 Jan 11;29(1):90-103. doi: 10.1016/j.ccell.2015.12.002.
Alice Soragni 1,  Deanna M Janzen 2,  Lisa M Johnson 1,  Anne G Lindgren 2,  Anh Thai-Quynh Nguyen 1,  Ekaterina Tiourin 2,  Angela B Soriaga 1,  Jing Lu 3,  Lin Jiang 1,  Kym F Faull 4,  Matteo Pellegrini 3,  Sanaz Memarzadeh 5,  David S Eisenberg 6
Affiliations

Affiliations

  • 1 Departments of Biological Chemistry and Chemistry and Biochemistry, UCLA-DOE Institute, HHMI, 611 South Charles E. Young Drive, Los Angeles, CA 90095-1570, USA.
  • 2 Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
  • 3 Molecular, Cell and Developmental Biology, University of California Los Angeles, Los Angeles, CA 90095, USA.
  • 4 Pasarow Mass Spectrometry Laboratory, Semel Institute, 405 Hilgard Avenue, Los Angeles, CA 90095, USA.
  • 5 Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angles, Los Angeles, CA 90095, USA; The VA Greater Los Angeles Health Care System, Los Angeles, CA 90073, USA. Electronic address: smemarzadeh@mednet.ucla.edu.
  • 6 Departments of Biological Chemistry and Chemistry and Biochemistry, UCLA-DOE Institute, HHMI, 611 South Charles E. Young Drive, Los Angeles, CA 90095-1570, USA. Electronic address: david@mbi.ucla.edu.
PMID: 26748848 DOI: 10.1016/j.ccell.2015.12.002
Abstract

Half of all human cancers lose p53 function by missense mutations, with an unknown fraction of these containing p53 in a self-aggregated amyloid-like state. Here we show that a cell-penetrating peptide, ReACp53, designed to inhibit p53 amyloid formation, rescues p53 function in Cancer cell lines and in organoids derived from high-grade serous ovarian carcinomas (HGSOC), an aggressive Cancer characterized by ubiquitous p53 mutations. Rescued p53 behaves similarly to its wild-type counterpart in regulating target genes, reducing cell proliferation and increasing cell death. Intraperitoneal administration decreases tumor proliferation and shrinks xenografts in vivo. Our data show the effectiveness of targeting a specific aggregation defect of p53 and its potential applicability to HGSOCs.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P0121
    99.87%, MDM-2/p53 p53 Activator